JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

Market Cap	2.08B
Revenue (ttm)	194.77M
Net Income (ttm)	-676.78M
Shares Out	405.53M
EPS (ttm)	-1.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,036,000
Average Volume	5,089,075
Open	4.90
Previous Close	5.13
Day's Range	4.71 - 5.21
52-Week Range	1.19 - 6.44
Beta	2.05
RSI	49.86
Earnings Date	Aug 28, 2025

About HKG:2126

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 281
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2126

Financial Performance

In 2024, HKG:2126's revenue was 158.22 million, a decrease of -8.99% compared to the previous year's 173.86 million. Losses were -590.62 million, -23.10% less than in 2023.

Financial numbers in CNY